B · Normal
[The first domestically produced long-acting RSV preventive monoclonal antibody is approved] On September 4, Ruiyang Biopharmaceutical Co., Ltd.’s bakumab injection (trade name: Inmulex) was approved for marketing by the State Food and Drug Administration on September 3. It is the first domestically produced long-acting preventive monoclonal antibody against respiratory syncytial virus (RSV) approved for marketing. Simcere Pharmaceuticals has the exclusive rights to commercialize this product in Greater China.
Comments